Abstract 1743P
Background
Gender disparities in academic research in oncology remain a persistent global challenge. There is a significant lack of research on gender inequity in Africa. GEORGiNA (“Gender Equity in Oncology Research” Group of North Africa) is a gender focusing bibliometric study that reviewed cancer research of North-African countries intending to build policy, recommendations, and gender equality actions in the field of cancer research.
Methods
A Pubmed-based bibliometric analysis was conducted over 2018-2022 period. Eligible articles had at least one author from a North-African country in the first or last position. Cancer researchers reviewed articles with authors from their own country to determine their gender accurately. A manual data extraction guide was developed and shared with collaborators to ensure consistent and accurate reporting. Factors associated with gender distribution were studied as appropriate.
Results
A total of 7,109 articles (2018-2022) published by North-African oncologists were included in the bibliometric analysis. Females represented 51% of first authors, with a notable women’s presence in Tunisia (71.9%). Morocco, Algeria, and Egypt demonstrated a fair distribution of female first authors with ratios close to 0.5, while Sudan and Libya exhibited male dominance with percentages of 62% and 70%, respectively. Among 37,019 of co-authors, 44.13 % (n=16,333) were females. Male oncologists were found to have significantly higher representation as principal investigators (PIs) in all countries (p < 0.001). Notably, there has been a remarkable increase in women taking lead authorship roles in recent years, including during the period of the COVID-19 pandemic. Male researchers dominated original articles as PIs (p < 0.001). Indeed, male had received more funding than females and published more open access science (p<0.01). There was a significant difference observed in the involvement of male authors (both first and last positions) in international collaboration compared to females in equivalent positions.
Conclusions
While women in cancer research appear to achieve a fair position, there are still barriers such as insufficient funding and limited international collaboration to drive progress towards gender equity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. El Bairi and GEORGiNA study collaborators.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23